- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01345084
Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab (NICAP)
A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck
Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups.
Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a phase III, superiority, national, open-label, randomized, and two-arm study.
Patients' enrollment will be performed only after approval by competent regulatory authorities and it will last up to 12 months.
All patients taking part in the study must sign an informed consent. The patients will have stage III or IV, unresectable head and neck SCC, performance status 0 or 1.
Randomization and treatment assignment will be performed by a company specifically contracted for such purpose and will be per research site and disease stage, 1:1
Undersøgelsestype
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Rio de Janeiro, Brasilien, 210041-030
- Hospital Federal de Bonsucesso
-
São Paulo, Brasilien, 01246-000
- Instituto do Câncer de São Paulo
-
-
Paraná
-
Curitiba, Paraná, Brasilien, 81520-060
- Hospital Erasto Gaetner
-
-
Rio Grande do Sul
-
porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
São Paulo
-
Barretos, São Paulo, Brasilien, 14784-400
- Fundação Pio XII - Hospital de Câncer de Barretos
-
Jau, São Paulo, Brasilien, 17210-120
- Hospital Amaral Carvalho
-
Mogi das Cruzes, São Paulo, Brasilien, 08730-500
- Centro Oncológico de Mogi das Cruzes
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Hospital de Base São José do Rio Preto
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
- Aged 18 to 75 years old;
- Histological or cytological confirmation of SCC in oral cavity, oropharynx, hypopharynx, or larynx;
- Stages III or IV disease
- Unresectability according to responsible surgeon or medical staff's opinion;
- Performance status 0 or 1
- Present indication for radiation therapy and chemotherapy treatment with cisplatin;
- Adequate hepatic, renal and medullar functions, indicated by:
- Life expectancy above 6 months.
Exclusion Criteria
- Presence of nasopharyngeal, paranasal sinuses, or salivary glands carcinoma;
- Presence of known distant metastasis;
- Presence of any other active neoplasm or history of any tumor diagnosed in the last 5 years
- Patients with inability to eat normally, in whom a gastric or enteral tubing was not possible at least 2 weeks before their enrollment in the study;
- Previous treatment with chemotherapy, radiation therapy, or EGFR inhibitors of any pharmacological class;
- Presence of serious comorbidity that, in the investigator's opinion, will put the patient at risk or will jeopardize protocol compliance;
- Active known seropositivity for HIV, hepatitis B or C
- Presence of a significant neurological or psychiatric disease, as per the investigator's judgment;
- Hypersensitivity or allergy to any of the study treatments;
- Presence of uncontrolled hypercalcemia;
- Pregnancy or breastfeeding;
- Female patients of childbearing potential who wish to become pregnant or are unwilling, as well as their partners, to use an appropriate contraceptive method throughout the study period;
- Participation in any clinical trial in the last 12 months.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Radiation therapy, cisplatin and nimotuzumab
Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months. Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses) |
200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
|
Aktiv komparator: Radiation therapy and cisplatin
Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses) |
66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
75 mg/m2, IV, doses every 3 weeks (a total of three doses)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 6 months
|
Local control of disease will be measured by magnetic resonance imaging (MRI) and physical examination 6 weeks after treatment end.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Complete clinical response rate
Tidsramme: 2 years
|
Progression-free survival; Incidence of locoregional failure; Site of the first recurrence or progression; Objective response rate assessment; EORTC quality of life questionnaires assessment; Incidence of several adverse events;
|
2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gustavo Girotto, Hospital de Base São José do Rio Preto
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EF 118
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Karcinom
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Metastatisk Urothelial Carcinom | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret nyrebækken Urothelial Carcinoma | Lokalt... og andre forholdForenede Stater
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.Trukket tilbageMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Uoperabelt nyrebækken Urothelial Carcinom | Uoperabelt Ureter Urothelial CarcinomaForenede Stater
-
All India Institute of Medical Sciences, New DelhiUkendtHOVED- OG NAKKEKRÆFT | CARCINOMA OROPHARYNX | CARCINOMA PYRIFORM SINUS | CARCINOMA LARYNXIndien
-
Barbara Ann Karmanos Cancer InstituteBristol-Myers SquibbAfsluttetStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)RekrutteringNyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
National Cancer Institute (NCI)AfsluttetNivolumab til behandling af patienter med tilbagevendende og/eller metastatisk nasopharyngeal cancerTilbagevendende nasopharynx carcinom | Stadie III Nasopharyngeal Carcinoma AJCC v7 | Stadie IV Nasopharyngeal Carcinoma AJCC v7 | Stadie IVA Nasopharyngeal Carcinoma AJCC v7 | Stadie IVB Nasopharyngeal Carcinoma AJCC v7 | Stadie IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal ikke-eratiniserende...Forenede Stater, Singapore, Kina
-
National Cancer Institute (NCI)RekrutteringStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Stadie II Blære Urothelial Carcinoma AJCC v6 og v7 | Muskelinvasiv blære Urothelial CarcinomForenede Stater
-
University of California, San FranciscoAmgenTrukket tilbageStadie 0a Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 er blæreurothelial karcinom AJCC v6 og v7 | Stadie I Blære Urothelial Carcinoma AJCC v6 og v7 | Stadie 0 Blære Urothelial Carcinoma AJCC v6 og v7Forenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStadie III Blære Urothelial Carcinoma AJCC v6 og v7 | Fase III Ureterkræft AJCC v7 | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret Ureter Urothelial Carcinoma | Lokalt avanceret Urothelial Carcinom | Lokaliseret nyrebækken og Ureter Urothelial Carcinoma | Stadie II Blære Urothelial... og andre forholdForenede Stater, Guam
Kliniske forsøg med Nimotuzumab
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Ukendt
-
Cancer Institute and Hospital, Chinese Academy...UkendtMavekræft | Samtidig kemoradioterapiKina
-
Peking Union Medical College HospitalIkke rekrutterer endnu
-
University of SaskatchewanRekrutteringKolorektal cancer | LungekræftCanada
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang... og andre samarbejdspartnereAfsluttet
-
University of SaskatchewanWestern Economic Diversification CanadaRekruttering
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Wuerzburg; Children... og andre samarbejdspartnereAfsluttet
-
YM BioSciencesCIMYM BioSciencesAfsluttetEn undersøgelse af nimotuzumab i kombination med strålebehandling hos patienter med hjernemetastaserMetastatisk ikke-småcellet lungekræftForenede Stater, Korea, Republikken, Canada, Cuba, Pakistan
-
Health Science Center of Xi'an Jiaotong UniversityRekruttering
-
The First Affiliated Hospital of Zhengzhou UniversityIkke rekrutterer endnuEsophageal pladecellekarcinomKina